Phase I reactions transform compounds through oxidation, reduction or hydrolysis
References Achaintre, D., Bulete, A., Cren-Olive, C., Li, L., Rinaldi, S., & Scalbert, A
Con esto dicho, el estudio proporciona una til tranquilidad sobre la seguridad de esta clase de medicamentos
How long can I use the same vial of reconstituted melanotan-1
Other risk factors that may increase vulnerability include: Long duration of diabetes (typically more than 10 years) Poor glycaemic control prior to starting GLP-1 therapy (HbA1c significantly above target) Rapid reduction in HbA1c (a drop of more than 2 percentage points [22 mmol/mol] within 36 months) Concurrent hypertension , especially if poorly controlled Diabetic kidney disease (nephropathy), which often correlates with retinopathy severity Previous history of retinal treatment (laser photocoagulation or intravitreal injections) People with type 2 diabetes but no retinopathy appear to have minimal risk of retinopathy progression based on current evidence
